Background. Ewing sarcoma (ES) is the most common chest wall malignancy in adolescents. Current therapy incorporates chemotherapy to treat systemic disease and radiotherapy to assist with local control. We sought to evaluate the timing of surgery and role of adjuvant radiotherapy. Methods. We reviewed the St. Jude Children's Research Hospital chest wall ES experience from 1979 to 2009. Patient demographics, tumor characteristics, treatment variables, and outcomes were analyzed with respect to timing of surgery and use of adjuvant radiotherapy. Results. Our cohort consisted of 36 patients with chest wall ES; median follow-up was 14.2 years, and 15-year estimate of overall survival was 66 %. In patients with localized disease, the timing of surgery (up-front vs. delayed) did not impact margin negativity or the use of adjuvant radiotherapy, but it did decrease the extent of chest wall resection. When considering radiotherapy in patients with localized disease, we found that patients who did not receive radiotherapy had smaller tumor size (median 6 vs. 10 cm) (p = 0.04) and were more likely to have had negative margins (p = 0.01) than patients who received adjuvant radiotherapy. One patient in each group developed a locoregional recurrence. The 15-year estimated of overall survival for patients who received adjuvant radiotherapy was 80 versus 100 % for those who did not. Conclusions. Delayed surgery decreased the extent of chest wall resection and helped define a patient population with favorable tumor biology. Patients with complete pathologic responses to chemotherapy, and those with tumors \8 cm and negative surgical margins may be spared adjuvant radiotherapy without any decrement in overall survival.
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Ewing sarcoma (ES) is the most common pediatric malignant chest wall tumor; about 10 % of ES arise from the chest wall. 1 Treatment of ES of the chest wall involves intense local therapy with surgical resection and/or radiotherapy, and chemotherapy to treat systemic disease. Historically, ES of the chest wall was treated with extensive chest wall resection involving multiple ribs and adjuvant radiotherapy. 2 This treatment strategy resulted in a significant number of incomplete surgical resections and complications such as scoliosis, chest wall deformities, pulmonary fibrosis, and secondary malignancies; thus, many began to advocate the use of preoperative chemotherapy. [2] [3] [4] [5] Complete surgical resection after neoadjuvant chemotherapy yielded excellent outcomes and quickly became the standard of care. 5, 6 Radiotherapy has long been considered a necessary component of treatment for ES of the chest wall. As longterm survival from ES has improved, more attention has been paid to the potential long-term complications of radiation, including pulmonary fibrosis, cardiac toxicity, and secondary malignancies. [7] [8] [9] Radiotherapy is at times used as the sole treatment modality for local control, but it is more frequently used in combination with surgical resection. Despite the prevalence of radiotherapy, there are no well-agreed-upon indications for its use in the adjuvant setting. Thus, the decision to administer or to not administer adjuvant radiotherapy is usually determined on a caseby-case basis. We reviewed the St. Jude Children's Research Hospital (SJCRH) experience with ES of the chest wall to evaluate the timing of surgical resection (up-front vs. delayed) and use of adjuvant radiotherapy on local control, event-free survival (EFS), and overall survival.
METHODS
A retrospective chart review was approved by the institutional review board for all patients with ES of the chest wall treated at SJCRH from 1979 to 2009. During that time, a total of 45 patients were treated. All patients were staged with either CT scan or MRI, with bone scan serving as an adjunct to cross-sectional imaging. Patients were considered to have ES of the chest wall if they had a chest wall tumor that was pathologically diagnosed as ES (osseous or extraosseous) or primitive neuroectodermal tumor of bone or soft tissue. All patients received multiagent chemotherapy, either vincristine, actinomycin D, cyclophosphamide, and doxorubicin (VACA), or VACA with alternating doses of ifosfamide and etoposide. Also, all patients received local therapy consisting of surgical resection, radiotherapy, or both. We excluded 3 patients whose tumors were secondary primary tumors, 3 patients referred to SJCRH after recurrence/progression for salvage therapy, 2 patients referred for bone marrow transplantation late in their disease course, and 1 patient who received chemotherapy only while visiting Memphis, Tennessee. Data regarding demographics (age, sex, race), presentation, primary tumor characteristics (location, size), staging, chemotherapy (timing, agents, doses), radiotherapy (timing, type, doses), surgery (timing, extent, margin status), recurrence (locoregional, distant), survival, cause of death, and follow-up were recorded.
Survival was defined as the time interval from date of diagnosis to date of death from any cause or to date of last contact. EFS was defined as the time interval from date of diagnosis to date of first event (relapsed or progressive disease or death from any cause) or to date of last contact for patients without events. Survival and EFS were estimated by the method of Kaplan and Meier. Standard errors were calculated by the method of Peto and Pike. 10 Outcome estimates are reported ± standard error. Differences in survival and EFS distributions by demographic and treatment factors were examined by the exact log rank test.
Local failure was defined as the time interval from date of diagnosis to date of local or regional disease recurrence or progression. Distant failure was defined as the time interval from date of diagnosis to date of distant disease recurrence or progression. The cumulative incidence of local failure (and of distant failure) was estimated.
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Treatment failure was defined as the time interval from date of diagnosis to date of treatment failure (relapsed or progressive disease or death related to disease). Diseasespecific survival was defined as the time interval from date of diagnosis to date of death from disease. The cumulative incidences of treatment failure and disease-specific survival were estimated. Differences in cumulative incidence curves were examined by Gray's test. 12 
RESULTS
Thirty-six patients with chest wall ES diagnosed between February 1979 and August 2009 were included in our study. Patient and tumor characteristics are shown in Table 1 . The majority of patients were male (n = 27, 75 %) and white (n = 30, 83 %), and the median age at diagnosis was 13.1 years (range 1.1-18.4 years). The most common presentations were pain (n = 29, 81 %) and a palpable mass (n = 11, 31 %). All patients had tumors arising from a rib or the soft tissue of the chest wall; there were no patients with sternal, vertebral, scapular, or clavicular sites of origin. At diagnosis, the median tumor size was 10 cm (range 4-19 cm). Eleven patients (31 %) had tumors \8 cm in diameter, and 25 patients (69 %) had tumors C8 cm in diameter. At diagnosis, 22 patients (61 %) had localized disease and 14 (39 %) had metastatic disease. Thirteen of 14 patients with metastatic disease at diagnosis had pulmonary (n = 10) or pleural (n = 3) metastases. All 36 patients received chemotherapy; 22 patients (61 %) received chemotherapy before definitive local therapy (7 had a complete pathologic response), and the other 14 patients (39 %) underwent up-front surgery and received chemotherapy postoperatively. Thirty-three (92 %) of 36 patients underwent surgical resection of their chest wall tumor a median of 2.7 months from diagnosis; the other 3 patients (8 %) received radiotherapy for local therapy instead. Negative surgical margins were achieved in 24 (73 %) of 33 patients. Radiotherapy was administered in either a neoadjuvant or adjuvant setting to 25 patients (69 %). Twenty-two (61 %) of 36 patients were alive at the time of analysis with a median follow-up from diagnosis of 14.2 years (range 1.0-30.9 years). The cumulative incidence of local failure and distant failure were estimated to be 21.9 ± 7.7 and 26.1 ± 8.4 % at 15 years, respectively. The 15-year estimates of EFS and survival were 56.3 ± 11.2 and 65.6 ± 10.7 %, respectively ( Fig. 1) . First events in the cohort included relapsed or progressive disease in 15 patients (6 locoregional, 8 distant, 1 simultaneous locoregional and distant) and death from other causes in 2 patients. Localized disease was marginally associated with improved EFS (p = 0.06) ( Table 2) . Tumor size of \ 8 cm and localized disease were marginally associated with improved overall survival (p = 0.10 and p = 0.06, respectively) ( Table 2) .
Timing of Surgical Resection
Twenty-two patients had localized disease at diagnosis and underwent either up-front or delayed therapy for local control. Nine patients underwent surgery before receiving any chemotherapy or radiotherapy. The other 13 patients received chemotherapy alone or chemotherapy and radiotherapy before definitive local therapy, surgery (n = 11), or radiotherapy (n = 2). The two patients who received radiotherapy for local therapy instead of surgery had tumors of \8 cm in diameter, had complete radiographic responses to neoadjuvant chemotherapy and radiotherapy, and received additional radiotherapy to the tumor bed for local therapy. For both patients, there was a question whether the ribs adjacent to the tumor were actually involved. One of these patients had a distant chest wall recurrence after 1.6 years, followed by disease progression, and died 1 year later. The other patient experienced a local recurrence after 10 years and died almost 2 years later from disease progression.
For the 20 patients with localized disease who underwent surgery, the median tumor size at diagnosis was 9 cm (range 4-11 cm) for the up-front group and 9 cm (range 4-17 cm) for the delayed group (p = 0.64) ( Table 3) . Patients with up-front surgery had a median of 3 ribs (range 0-4) resected compared to a median of 2 ribs (range 0-3) for the delayed group (Table 3) . Synthetic material was used to reconstruct/close the chest wall in 5 (56 %) of 9 patients and 5 (45 %) of 11 in the delayed group (Table 3) . Negative surgical margins were achieved in 6 (67 %) of 9 patients in the up-front group and 8 (73 %) of 11 patients in the delayed group, 4 of whom demonstrated a complete pathologic response. Adjuvant radiotherapy was administered to 3 (33 %) of 9 patients who underwent up-front surgery; these 3 patients all had positive margins. Seven (64 %) of 11 patients in the delayed-surgery group received adjuvant radiotherapy; 3 patients had positive margins, 1 patient had spinal cord compression, 1 patient had less than 20 % necrosis seen on the pathologic specimen, 1 patient had close margins, and 1 patient underwent pulmonary lobectomy at the initial operation with negative margins. Locoregional failure occurred in 1 (11 %) of 9 patients in the up-front group with a pleural-based recurrence, and 1 (9 %) of 11 in the delayed group with a local recurrence in the chest wall. Of note, both of these patients had received adjuvant radiotherapy for positive surgical margins. There was no evidence of a significant difference in EFS (p = 0.64). However, there was evidence of a marginally significant difference in survival distributions among localized patients in the up-front and the delayed therapy groups (p = 0.058); the 15-year estimate for patients who underwent up-front surgery was 100 %, compared to 81.8 ± 14.2 % for patients with delayed surgery. However, one patient in the delayed group died from an unrelated nonmalignant cause, and an additional patient died from complications after developing acute lymphoblastic leukemia. Thus, when considering only deaths related to ES, there was no evidence of a significant difference in disease-specific survival among the delayed versus up-front surgery groups (p = 0.42).
Adjuvant Radiotherapy
Of the 22 patients with localized disease, 9 did not receive radiotherapy and 13 were treated with radiotherapy. Of the 13 patients receiving radiotherapy, 10 received adjuvant radiotherapy and 3 received neoadjuvant radiotherapy, 2 of whom received additional radiotherapy as definitive local therapy instead of surgery. We excluded the latter 3 patients from the analysis so we could compare patients who did not receive radiotherapy to those who received adjuvant radiotherapy. There was a significant difference in median tumor size observed between patients who did not receive (6 cm, range 4-10 cm) and those who did receive (10 cm, range 5-14 cm) adjuvant radiotherapy (p = 0.04) ( Table 4 ). All 9 patients who did not receive radiotherapy had negative surgical margins, with 3 having a complete pathologic response. Four of 10 patients treated with adjuvant radiotherapy had negative margins, and 1 patient had a complete pathologic response. In the noradiotherapy group, 1 patient with a tumor of [8 cm and negative surgical margins developed a locoregional recurrence. One patient in the adjuvant radiotherapy group developed a local recurrence; he had a tumor of[8 cm and a positive surgical margin. Also, 2 patients in each group developed distant recurrence, yielding a 15-year estimated EFS of 74.1 ± 15.4 % for the no-radiotherapy group and 80.0 ± 14.6 % for the adjuvant radiotherapy group (p = 0.69). The 15-year estimates of survival were 100 % for the no-radiotherapy group and 80.0 ± 14.6 % for the adjuvant radiotherapy group (p = 0.35).
DISCUSSION
In 1979, a treatment protocol was instituted at SJCRH for patients with ES that required multiagent chemotherapy (vincristine, actinomycin D, cyclophosphamide, and doxorubicin) be provided to all patients. Here we present the ensuing 30 years of experience with ES of the chest wall. Fourteen patients (39 %) had metastatic disease at diagnosis. For the entire cohort, the median follow-up was 14.2 years. The 15-year estimates of EFS and survival were 56 and 66 %, respectively. We identified localized disease and tumor size to be factors marginally associated with EFS and survival. Previously, patient age at diagnosis, site of disease, initial tumor size, chemotherapy administered, and tissue of origin have been shown to be associated with outcomes in patients with ES and/or those with chest wall primary disease.
1,4,13-16 Also, Lin et al. found that response to chemotherapy was an important predictor of local recurrence after surgical resection of ES. 17 We focused our attention on the 22 patients with localized disease. Two of these patients with tumors of \8 cm received radiotherapy as the sole modality for local control. They both demonstrated complete radiographic responses, but they ultimately developed disease progression and died, with overall survivals of 2.5 and 11.5 years. For the remaining 20 patients, all of whom underwent surgical resection, the estimated 15-year survival was 90 %. An estimated 5-year survival of 61 % for patients with nonmetastatic chest wall ES has been reported. 4, 17 We further analyzed the patients with localized disease, specifically addressing the timing of surgical resection and the role of adjuvant radiotherapy.
Surgical resection of ES tumors of the chest wall can be performed as the initial therapy (up-front surgery) or after the patient has received neoadjuvant chemotherapy (delayed surgery). Approximately half of our patients with localized disease underwent up-front surgical resection. Patients who underwent up-front surgery had larger chest wall resections, with a median of 3 ribs resected compared to 2 ribs in the delayed group (p = 0.36). In 1988, Rao et al. reported the early SJCRH experience and noted that cases of good response to neoadjuvant chemotherapy often only required resection of the involved rib and patients were spared a larger chest wall resection. 2 The additional 20? years of experience we report here support this initial observation. Comparable margin negativity rates were found between the up-front and delayed groups (67 and 73 %, respectively). This 67 % margin negativity rate for patients who underwent up-front surgery is higher than the 50 % reported by Shamberger et al. 5 Larger chest wall resections, including multiple ribs, could explain the high margin negativity rate in our cohort. Consequently, only 3 patients (33 %) who underwent up-front surgery received adjuvant radiotherapy. Curiously, 7 patients (64 %) with delayed surgical resection received adjuvant radiotherapy. One possible explanation for the fact that fewer patients in the up-front group received adjuvant radiotherapy is that many of these patients underwent their operation early on in our experience, when the use of adjuvant radiotherapy was less prevalent. Importantly, 4 (36 %) of 11 of the patients who underwent delayed surgical resection were found to have a complete pathologic response. Locoregional failure was infrequent, with only 1 patient in each group developing a local recurrence. We found no significant difference in EFS between the groups. Shamberger et al. also found that local recurrence rate and EFS did not significantly differ between patients who underwent upfront and delayed surgical resection. 4 As mentioned earlier, patients with localized disease treated with surgical resection (up-front or delayed surgery) and chemotherapy with or without radiotherapy had excellent long-term survival, with an estimated 15-year survival of 90 %.
Next, we wanted to elucidate the impact and role of adjuvant radiotherapy. Among patients with localized disease who underwent surgery, 9 patients did not receive radiotherapy, while 10 received adjuvant radiotherapy. In our cohort, patients who did not receive radiotherapy had significantly smaller tumors and all had negative surgical margins, with 3 patients experiencing a complete pathologic response. One patient in the no-adjuvant-radiotherapy group developed a pleural-based locoregional recurrence; this patient had a 10-cm tumor at diagnosis. EFS did not differ between the no-radiotherapy group and the adjuvant radiotherapy group (15-year estimates 74 ± 15 and 80 ± 15 %, respectively; p = 0.69); most of the events were distant recurrences. Schuck et al. examined a cohort of patients with localized disease and compared those who received adjuvant radiotherapy to those who did not. 14 The radiotherapy group had a higher percentage of patients with tumor pleural infiltration, pleural effusion, and intraoperative tumor contamination of the pleural cavity than the noradiotherapy group. Of note, the no-radiotherapy group had significantly larger tumors than the radiotherapy group. The 7-year EFS was 63 % for the radiotherapy group and 46 % for the no-radiotherapy group (p = 0.13). Thus, the authors concluded that adjuvant hemithorax radiotherapy should be recommended. 15 When interpreting the results of this study, we must keep in mind that the patients who did not receive radiotherapy had larger tumors, and thus they are expected to have a worse EFS. Finally, in our cohort, the estimated 15-year survival rate for those who did not receive adjuvant radiotherapy was 100 %, compared to 80 % for those who received adjuvant radiotherapy. Thus, there is a group of patients who likely receive minimal benefit from adjuvant radiotherapy.
Limitations of our study include its retrospective design. Also, SJCRH is a large referral center, so our patient population may have more advanced or complicated disease than other hospitals, which would ultimately effect treatment strategies and outcomes. Fortunately, the chemotherapeutic regimen has been standardized at SJCRH since 1979 with little variation. However, the use of radiotherapy was less standardized and was frequently evaluated on a case-by-case basis. Even though our review encompasses the last 30 years of experience at SJCRH, the sample size is fairly small, with only 36 patients.
In conclusion, ES of the chest wall is a complex problem requiring a multidisciplinary approach with multimodal therapy, but long-term survival is achievable. High rates of margin negativity can be achieved with up-front surgery, but this requires large chest wall resections. Administering chemotherapy first and performing a delayed surgical resection decreases the extent of chest wall resection and helps define a patient population with favorable tumor biology (i.e., complete pathologic response). Adjuvant radiotherapy plays a vital role in the treatment of patients with ES of the chest wall, but there are patient populations who have excellent outcomes in the absence of adjuvant radiotherapy. It seems that in addition to patients with complete pathologic responses to induction chemotherapy, patients with tumors of \8 cm and negative surgical margins can safely receive surgical resection as the sole mode of local therapy. In our cohort, these two patient populations included 45 % of all patients with localized disease. Thus, a significant portion of patients with ES of the chest wall could be spared adjuvant radiotherapy and its potential long-term complications. Further prospective studies are needed to determine if it is safe to omit adjuvant radiotherapy from the treatment regimen for these patient populations.
